These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

433 related items for PubMed ID: 28222447

  • 1. Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer.
    Igawa S, Sato Y, Ryuge S, Ichinoe M, Katono K, Hiyoshi Y, Otani S, Nagashio R, Nakashima H, Katagiri M, Sasaki J, Murakumo Y, Satoh Y, Masuda N.
    Oncology; 2017; 92(5):283-290. PubMed ID: 28222447
    [Abstract] [Full Text] [Related]

  • 2. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
    Schmidt LH, Kümmel A, Görlich D, Mohr M, Bröckling S, Mikesch JH, Grünewald I, Marra A, Schultheis AM, Wardelmann E, Müller-Tidow C, Spieker T, Schliemann C, Berdel WE, Wiewrodt R, Hartmann W.
    PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
    [Abstract] [Full Text] [Related]

  • 3. The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.
    Takada K, Okamoto T, Toyokawa G, Kozuma Y, Matsubara T, Haratake N, Akamine T, Takamori S, Katsura M, Shoji F, Oda Y, Maehara Y.
    Lung Cancer; 2017 Feb; 104():7-15. PubMed ID: 28213003
    [Abstract] [Full Text] [Related]

  • 4. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
    Takada K, Toyokawa G, Okamoto T, Shimokawa M, Kozuma Y, Matsubara T, Haratake N, Akamine T, Takamori S, Katsura M, Shoji F, Oda Y, Maehara Y.
    Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951
    [Abstract] [Full Text] [Related]

  • 5. Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non-small cell lung cancer.
    Nagasaki Y, Taki T, Nomura K, Tane K, Miyoshi T, Samejima J, Aokage K, Ohtani-Kim SJ, Kojima M, Sakashita S, Sakamoto N, Ishikawa S, Suzuki K, Tsuboi M, Ishii G.
    J Natl Cancer Inst; 2024 Jul 01; 116(7):1158-1168. PubMed ID: 38459590
    [Abstract] [Full Text] [Related]

  • 6. Clinical significance of ≥ 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients.
    Li W, Song P, Guo L, Liu X, Guo C, Ying J, Gao S.
    Thorac Cancer; 2019 Feb 01; 10(2):175-182. PubMed ID: 30536734
    [Abstract] [Full Text] [Related]

  • 7. PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer.
    Ikeda S, Okamoto T, Okano S, Umemoto Y, Tagawa T, Morodomi Y, Kohno M, Shimamatsu S, Kitahara H, Suzuki Y, Fujishita T, Maehara Y.
    J Thorac Oncol; 2016 Jan 01; 11(1):62-71. PubMed ID: 26762740
    [Abstract] [Full Text] [Related]

  • 8. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
    Cooper WA, Tran T, Vilain RE, Madore J, Selinger CI, Kohonen-Corish M, Yip P, Yu B, O'Toole SA, McCaughan BC, Yearley JH, Horvath LG, Kao S, Boyer M, Scolyer RA.
    Lung Cancer; 2015 Aug 01; 89(2):181-8. PubMed ID: 26024796
    [Abstract] [Full Text] [Related]

  • 9. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC, Midha A, Mistry A, Sabalos C, Schechter N, Li X, Jin X, Steele KE, Robbins PB, Blake-Haskins JA, Walker J.
    Diagn Pathol; 2016 Oct 08; 11(1):95. PubMed ID: 27717372
    [Abstract] [Full Text] [Related]

  • 10. Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.
    Sacher AG, Gandhi L.
    JAMA Oncol; 2016 Sep 01; 2(9):1217-22. PubMed ID: 27310809
    [Abstract] [Full Text] [Related]

  • 11. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.
    Yang CY, Lin MW, Chang YL, Wu CT, Yang PC.
    Eur J Cancer; 2014 May 01; 50(7):1361-9. PubMed ID: 24548766
    [Abstract] [Full Text] [Related]

  • 12. Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers.
    Akamine T, Takada K, Toyokawa G, Kinoshita F, Matsubara T, Kozuma Y, Haratake N, Takamori S, Hirai F, Tagawa T, Okamoto T, Yoneshima Y, Okamoto I, Shimokawa M, Oda Y, Nakanishi Y, Maehara Y.
    Surg Oncol; 2018 Mar 01; 27(1):88-94. PubMed ID: 29549910
    [Abstract] [Full Text] [Related]

  • 13. A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma.
    Matsubara T, Takada K, Azuma K, Takamori S, Toyokawa G, Haro A, Osoegawa A, Tagawa T, Kawahara A, Akiba J, Okamoto I, Nakanishi Y, Oda Y, Hoshino T, Maehara Y.
    Ann Surg Oncol; 2019 Jun 01; 26(6):1925-1933. PubMed ID: 30815803
    [Abstract] [Full Text] [Related]

  • 14. Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
    Sepesi B, Cuentas EP, Canales JR, Behrens C, Correa AM, Vaporciyan A, Weissferdt A, Kalhor N, Moran C, Swisher S, Wistuba I.
    Semin Thorac Cardiovasc Surg; 2019 Jun 01; 29(3):408-415. PubMed ID: 29195578
    [Abstract] [Full Text] [Related]

  • 15. Significance of PD-L1 expression in pulmonary metastases from head and neck squamous cell carcinoma.
    Okada S, Itoh K, Ishihara S, Shimada J, Kato D, Tsunezuka H, Miyata N, Hirano S, Teramukai S, Inoue M.
    Surg Oncol; 2018 Jun 01; 27(2):259-265. PubMed ID: 29937180
    [Abstract] [Full Text] [Related]

  • 16. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
    Yeo MK, Choi SY, Seong IO, Suh KS, Kim JM, Kim KH.
    Hum Pathol; 2017 Oct 01; 68():103-111. PubMed ID: 28851662
    [Abstract] [Full Text] [Related]

  • 17. Biphasic prognostic significance of PD-L1 expression status in patients with early- and locally advanced-stage non-small cell lung cancer.
    Teramoto K, Igarashi T, Kataoka Y, Ishida M, Hanaoka J, Sumimoto H, Daigo Y.
    Cancer Immunol Immunother; 2021 Apr 01; 70(4):1063-1074. PubMed ID: 33113005
    [Abstract] [Full Text] [Related]

  • 18. The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs.
    Tang Y, Fang W, Zhang Y, Hong S, Kang S, Yan Y, Chen N, Zhan J, He X, Qin T, Li G, Tang W, Peng P, Zhang L.
    Oncotarget; 2015 Jun 10; 6(16):14209-19. PubMed ID: 25895031
    [Abstract] [Full Text] [Related]

  • 19. An Immunohistochemical Analysis of PD-L1 Protein Expression in Surgically Resected Small Cell Lung Cancer Using Different Antibodies and Criteria.
    Takada K, Toyokawa G, Okamoto T, Akamine T, Takamori S, Katsura M, Fujishita T, Shoji F, Oda Y, Maehara Y.
    Anticancer Res; 2016 Jul 10; 36(7):3409-12. PubMed ID: 27354600
    [Abstract] [Full Text] [Related]

  • 20. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
    Kim S, Kim MY, Koh J, Go H, Lee DS, Jeon YK, Chung DH.
    Eur J Cancer; 2015 Nov 10; 51(17):2698-707. PubMed ID: 26329973
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.